Author | Kathleen Moore, MD | OncLive

Author | Kathleen Moore, MD

Articles

Dr. Moore on Early-Phase Data With Mirvetuximab Soravtansine in Ovarian Cancer

April 03, 2020

Video

Kathleen Moore, MD, discusses the early phase data that led to the development of the phase III FORWARD I/ GOG 3011 trial in ovarian cancer.

Dr. Moore on Safety Profile of Mirvetuximab Soravtansine in Ovarian Cancer

March 27, 2020

Video

Kathleen Moore, MD, discusses the safety profile of mirvetuximab soravtansine, an antibody-drug conjugate that targets the FRα transmembrane protein, in ovarian cancer.

Dr. Moore on the Role of Mirvetuximab Soravtansine in Ovarian Cancer

March 04, 2020

Video

Kathleen Moore, MD, director, Oklahoma TSET Phase I Clinical Trials Program, and associate professor, Section of Gynecologic Oncology, Jim and Christy Everest Endowed Chair in Cancer Research, director, Gynecologic Oncology Fellowship Program, associate director of Clinical Research, and medical director of the Clinical Trials Office, at Stephenson Cancer Center, discusses the role of mirvetuximab soravtansine in platinum-resistant ovarian cancer.

Dr. Moore on Results of the FORWARD I/GOG 3011 Trial in Ovarian Cancer

February 14, 2020

Video

Kathleen Moore, MD, discusses topline findings from the phase III FORWARD I/GOG 3011 trial in ovarian cancer.

x